Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Consultings Executive Insights will explore how payers should strategize their approach to glucagon-like peptide-1 agonists (GLP-1s) as they weigh rising consumer demand and increasing pharma supply with recognition of longer-term return on investment (ROI) opportunity
Renal effects: Rare cases of interstitial nephritis and capillary necrosis have been reported in patients treated with diclofenac
7 Exenatide is the most prevalent GLP-1 in clinical trials for AD and PD treatments
Importantly for the availability of coverage across the workforce, the share of firms with 5,000 or more workers covering these medications for weight loss increased significantly over the last year (from 28% in 2024 to 43% in 2025)
US$ 20.99
US$ 25.79
US$ 29.41
US$ 20.06
US$ 26.82
US$ 27.69
US$ 27.59
US$ 28.05
